We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


ExonHit Will Participate in the MAPT Study for the Prevention of Cognitive Decline in Old People

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute
ExonHit Therapeutics together with Toulouse University Hospital and l’Institut de Recherche Pierre Fabre (IRPF) will participate in the Multidomain Alzheimer Preventive Trial (MAPT).

The study’s main objective is to assess the efficacy of a multidomain (nutrition, physical exercise, cognitive stimulation) intervention associated with an omega-3 treatment in preventing the decline of cognitive functions in aged and frail individuals.

“We are going to apply our validated AclarusDx™ diagnostic platform to the study samples in order to identify early blood biomarkers of Alzheimer’s disease,” commented Loic Maurel, M.D., President of the Management Board of ExonHit Therapeutics. He added: “Access to such biomarkers would be a major asset for developing new drugs against this disease.”

The clinical study, which includes several memory centers in France, is lead by Professor Bruno Vellas, M.D., Head of the Alzheimer’s Disease Clinical Research Center and of the Gerontopole, Toulouse University Hospital, France.

“Early detection of Alzheimer’s disease, before signs of dementia appear and taking action at a very early stage is key to an improved patient care,” stated Professor Vellas.

Over the course of 3 years, 1,200 frail individuals, of both genders and aged 70 or more will be monitored. During this period, the status of their cognitive functions and of their functional capacity will be assessed in order to identify the ones who evolve towards dementia, in particular one of an Alzheimer’s type, and to evaluate the preventive measures that are tested.

Annual blood samplings will allow for transcriptome analysis in order to:

• Develop a signature that will identify asymptomatic subjects at risk of having an impairment of their cognitive functions, which could evolve towards a dementia (Alzheimer’s or other) and

• Search for new biological markers for the diagnosis and prognosis of cognitive diseases such as Alzheimer’s, with the long-term objective of developing new, more effective treatments.

Financial terms of the 3-party agreement were not disclosed.